| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 105 | ₹14,700 |
| HNI / NII | 14 | 1,470 | ₹2,05,800 |
| bHNI / bNII | 69 | 7,245 | ₹10,14,300 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 54,45,000 (50.00%) | — | ₹7,623.00 Cr |
| NII / HNI (Total) | — | 16,33,500 (15.00%) | — | ₹2,286.90 Cr |
| Retail Investors | — | 38,11,500 (35.00%) | — | ₹5,336.10 Cr |
| Total ** | — | 1,08,90,000 (100.00%) | — | ₹152,460.00 Cr |
| Metric | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 183.78 | 293.47 | 338.77 |
| PAT | 30.59 | 27.50 | 29.00 |
| EBITDA | — | — | — |
| Net Worth | 88.58 | 71.46 | 100.49 |
| Total Assets | 106.31 | 181.81 | 212.76 |
| Reserves | — | — | — |
| Borrowings | 0.35 | 60.68 | 59.40 |
Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.
The company's manufacturing unit is located in Palghar, Maharashtra, spread across 2,000 sq. mts. of land with an aggregate annual total installed capacity of 9,000 MT per annum. Valiant Laboratories also has an R&D Facility, equipped with an analytical laboratory and infrastructure for developmental activities in existing products.
For the Fiscal 2023, Fiscal 2022 and Fiscal 2021, Valiant Laboratories revenue from operations was Rs. 3,339.10 million, Rs. 2,915.23 million and Rs. 1,823.69 million, respectively.
Valiant Laboratories Limited imports Para Amino Phenol, being the raw material for the manufacture of Paracetamol from China and Cambodia.
As of April 30, 2023, Valiant Laboratories has 86 employees.